韦兰德TIA1突变使胰岛素产生细胞脱差 - - 由GLP-1受体激动剂逆转
Tongjian Zhao1, Jing Cen1, Xuan Wang1
1Department of Medical Cell Biology, Uppsala University, Box 571, SE-751 23, Uppsala, Sweden.
The Journal of biological chemistry
|March 5, 2026
概括
TIA1 E384K突变通过增加MYC水平和细胞增殖导致β细胞脱差. GLP-1受体激应逆转了这种情况,建议新的糖尿病治疗策略.
科学领域:
- 分子生物学分子生物学
- 细胞生物学 细胞生物学
- 内分泌学 在内分泌学.
背景情况:
- RNA结合蛋白TIAR和TIA1影响β细胞功能.
- 这种TIA1 E384K突变与Welander远端肌肉病症有关.
- 了解TIA1在β细胞中的作用对于糖尿病研究至关重要.
研究的目的:
- 研究TIA1 E384K突变对产生人类胰岛素的EndoC-βH1细胞的影响.
- 阐明TIA1突变诱导的β细胞功能障碍背后的分子机制.
- 探索TIA1相关β细胞损伤的潜在治疗干预措施.
主要方法:
- 使用原始编辑来创建同卵性E384K TIA1突变EndoC-βH1细胞克隆.
- 评估细胞活力,压力颗粒形成,呼吸和增殖.
- 分析了基因表达 (MYC,GLP-1R,β细胞基因,PAX4/ARX),蛋白质水平,以及胰岛素/葡萄糖的产生.
- 研究了MYC mRNA与TIA1的结合以及MYC下调的作用.
- 评估了GLP-1受体激动剂 (利拉格卢提德) 治疗的疗效.
主要成果:
- TIA1 E384K突变没有影响压力颗粒的形成或细胞死亡.
- 突变细胞表现出增加的呼吸,增殖和MYC水平.
- 观察到GLP-1受体表达的减少,"不允许"基因的增加,益胰岛素处理受损,胰岛素含量/释放的减少和葡萄糖生成的增加.
- TIA1 E384K突变减少了MYC mRNA与TIA1.1的结合.
- 下调MYC使胰岛素/葡萄糖和PAX4/ARX比率正常化.
- 利拉格卢提德治疗恢复了胰岛素的产生,并逆转了β细胞的脱差.
结论:
- 在TIA1 E384K突变驱动贝塔细胞脱差通过高MYC和增殖.
- 功能障碍的RNA结合蛋白可能导致糖尿病患者的胰岛素生产受损.
- GLP-1受体激动症在逆转TIA1诱导的β细胞功能障碍和脱差方面表现有前途,为糖尿病提供潜在的治疗途径.
更多相关视频
相关概念视频
Glucagon-like Receptor Agonists
1.1K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.1K
Forced Transdifferentiation
2.4K
Transdifferentiation, also known as lineage reprogramming, was first discovered by Selman and Kafatos in 1974 in silkmoths. They observed that the moths’ cuticle-producing cells transformed into salt-producing cells. Many such cases of natural transdifferentiation occur in organisms. In humans, pancreatic alpha cells can become beta cells. In newts, the loss of the eye’s lens causes the pigmented epithelial cells to transdifferentiate into the lens cells.
Artificial...
Artificial...
2.4K
Dipeptidyl Peptidase 4 Inhibitors
814
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
814
Insulin: The Receptor and Signaling Pathways
5.4K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
5.4K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
2.9K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
2.9K


